Frankfurt
31.01.25
08:08 Uhr
1,456 Euro
+0,004
+0,28 %
+0,28 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Diamyd Medical AB (publ): Quarterly Report 1 24/25 | 11 | GlobeNewswire (Europe) | September 2024 - November 2024, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical's B-share is traded... ► Artikel lesen | |
| 21.01. | DIAMYD MEDICAL AB: South Korea to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 1 | Cision News | ||
| 13.01. | Diamyd Medical AB: Diamyd Medical updates U.S. market potential for Diamyd | 328 | PR Newswire | STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- Diamyd Medical has released an updated analysis of the commercial potential for its lead product candidate, the precision immunotherapy Diamyd® (rhGAD65/alum)... ► Artikel lesen | |
| 10.01. | Diamyd Medical AB: Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd following FDA Type C Meeting | 1.223 | PR Newswire | STOCKHOLM, Jan. 10, 2025 /PRNewswire/ -- Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration... ► Artikel lesen | |
| 09.01. | DIAMYD MEDICAL AB: Renowned immunology investigator, Alice Long, joins Diamyd Medical's Scientific Advisory Board | 2 | Cision News | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 07.01. | Diamyd Medical AB (publ): New publication highlights safety and potential benefits of redosing Diamyd precision medicine for Type 1 Diabetes | 102 | GlobeNewswire (Europe) | Diamyd Medical announces the publication of the article titled "Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial" in the peer-reviewed journal International... ► Artikel lesen | |
| 23.12.24 | DIAMYD MEDICAL AB: Renowned Diabetes Investigator, Emily Sims, Joins Diamyd Medical's Scientific Advisory Board | 1 | Cision News | ||
| 13.12.24 | Diamyd Medical AB: Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process | 344 | PR Newswire | STOCKHOLM, Dec. 13, 2024 /PRNewswire/ -- Diamyd Medical today announced a positive in-person Type C meeting with the U.S. Food and Drug Administration (FDA), where alignment was achieved... ► Artikel lesen | |
| 05.12.24 | Bulletin from Annual General Meeting of Diamyd Medical AB | 2 | Cision News | ||
| 03.12.24 | DIAMYD MEDICAL AB: Annual Report 2023/2024 | 2 | Cision News | ||
| 25.11.24 | DIAMYD MEDICAL AB: Article published by ASSET, coordinated by Diamyd Medical, advocates for national screening programs in Sweden for early detection of Type 1 Diabetes | 1 | Cision News | ||
| 21.11.24 | Diamyd Medical AB: Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial | 238 | PR Newswire | STOCKHOLM, Nov. 21, 2024 /PRNewswire/ -- 180 patients have now been recruited in the precision medicine Phase 3 trial DIAGNODE-3, exceeding the recruitment target set for the planned early... ► Artikel lesen | |
| 15.11.24 | DIAMYD MEDICAL AB: Conference on the future of Type 1 Diabetes screening organized as part of the ASSET partnership coordinated by Diamyd Medical | 1 | Cision News | ||
| 14.11.24 | DIAMYD MEDICAL AB: Diamyd Medical recognizes World Diabetes Day | 1 | Cision News | ||
| 14.11.24 | DIAMYD MEDICAL AB: Information about the Annual Report 2023/2024 | 2 | Cision News | ||
| 06.11.24 | Diamyd Medical AB: In-depth analysis showing robust Diamyd treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress | 296 | PR Newswire | STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- (IDS) Congress in Bruges, Belgium. The analysis will be presented at a Satellite Symposium organized by Abbott. The results support the robustness... ► Artikel lesen | |
| 06.11.24 | DIAMYD MEDICAL AB: In-depth analysis showing robust Diamyd[®] treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress | 2 | Cision News | ||
| 05.11.24 | DIAMYD MEDICAL AB: Diamyd Medical and INNODIA partner for Type 1 Diabetes awareness and patient recruitment for the DIAGNODE-3 precision medicine trial | 1 | Cision News | ||
| 14.10.24 | DIAMYD MEDICAL AB: Diamyd Medical highlights precision medicine approach for Type 1 Diabetes at the scientific conferences ISPAD and IDS | 1 | Cision News | ||
| 09.10.24 | Diamyd Medical AB (publ): Year-End Report 23/24 | 106 | GlobeNewswire (Europe) | September 2023 - August 2024, Diamyd Medical AB (publ), Fiscal year 2023/2024
Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical's B-share is traded on... ► Artikel lesen |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 177,18 | -0,07 % | Ihre wichtigsten Termine: Alle Augen auf: Samsung Elelctronics, Thyssenkrupp, Exxon Mobil, Chevron& AbbVie | © Foto: Ahn Young-joon/APGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 02:00... ► Artikel lesen | |
| INNOCAN PHARMA | 0,107 | +0,94 % | Breaking News: Wichtige Zertifizierung und Verkaufsmeilenstein! | ||
| ABBOTT LABORATORIES | 123,22 | -0,08 % | Comedy Central holt Abbott Elementary ins Free-TV | ||
| ARZNEIWERK AG VIDA | 0,505 | +4,34 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß §§ 114-117 WpHG
Berlin (pta/20.08.2024/15:00)... ► Artikel lesen | |
| ZOETIS | 164,36 | -0,21 % | Zoetis Inc. (ZTS): A Bull Case Theory | ||
| CRESCO LABS | 0,881 | -1,29 % | Cresco Labs Demonstrates Success of Cash Flow Focused Strategy with Third Quarter 2024 Financial Results | Record quarterly operating cash flow of $49 million and year to date operating cashflow of $103 million, an increase of 66% from the prior year period
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF)... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 0,430 | +14,67 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
| CSPC PHARMA | 0,565 | +2,69 % | CSPC Pharmaceutical Group-Aktie heute stark gefragt: Kurs legt deutlich zu (0,5286 €) | Zu den großen Gewinnern am Aktienmarkt zählt am Dienstag das Wertpapier der CSPC Pharmaceutical Group . Der Kurs des Papiers legt kräftig zu. Eine Steigerung um 6,87 Prozent - mit diesem Wertanstieg... ► Artikel lesen | |
| AMARIN | 0,510 | +4,94 % | Amarin Corporation plc: Amarin Appoints Peter Fishman Chief Financial Officer | DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,818 | +2,19 % | Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis | SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 102,55 | 0,00 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Announces FDA Approval of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults | A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours 85% and 77% of patients treated... ► Artikel lesen | |
| WUXI BIOLOGICS | 2,323 | -1,65 % | WuXi Biologics-Aktie leicht im Plus (2,09 €) | Das Wertpapier von WuXi Biologics notiert am Donnerstag etwas fester. Das Wertpapier kostete zuletzt 2,09 Euro. Jahreschart der WuXi Biologics Inc-Aktie, Stand 09.01.2025 Freuen können sich gegenwärtig... ► Artikel lesen | |
| JAGUAR HEALTH | 0,884 | -1,73 % | Jaguar Health, Inc.: Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO | Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 18,150 | +0,86 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome | -- Filing marks company's first Marketing Authorization Application in Europe
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization... ► Artikel lesen | |
| DAIICHI SANKYO | 27,130 | -0,15 % | Daiichi Sankyo: Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer | Recommendation based on TROPION-Breast01 results showing Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan reduced risk of disease progression or death by 37% versus chemotherapy
Datopotamab... ► Artikel lesen |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,28 % bei einem Aktienkurs von 1,456 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.
